Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ: AQST) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, a virtual event on February 25-26, 2026. Management will present on February 26 at 12:00 PM ET and will hold investor one-on-ones the same day.
A webcast will be available on the company’s Investors "Events and Presentations" page, with a replay accessible for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – AQST
On the day this news was published, AQST gained 0.51%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AQST’s modest -0.25% move occurs alongside mixed peer action: in its peer set, some names are up (e.g., ORGO 0.76%, SIGA 0.15%) while others are down (ESPR -0.57%, EOLS -0.68%). Momentum scanner peers show AKBA up 1.69%, ETON up 3.12%, and KMDA down 3.30%, suggesting stock-specific rather than broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 20 | Clinical data update | Positive | +0.4% | Planned presentation of new Anaphylm clinical data at AAAAI meeting. |
| Feb 18 | Management appointment | Positive | -1.3% | Appointment of award‑winning allergist as Chief Medical Officer. |
| Feb 02 | FDA CRL issued | Negative | +39.0% | FDA Complete Response Letter for Anaphylm focused on packaging and PK study. |
| Jan 09 | Regulatory update | Negative | -37.0% | FDA identified deficiencies in Anaphylm NDA ahead of Jan 31, 2026 PDUFA date. |
| Nov 24 | Conference participation | Neutral | +1.1% | Participation in Piper Sandler conference with Anaphylm-focused fireside chat. |
News tied to Anaphylm’s FDA review has driven the largest moves, with both sharp selloffs and rallies, while conference participation and routine updates have corresponded to relatively small price changes.
Over the last several months, AQST’s trajectory has been dominated by regulatory developments for Anaphylm. An 8-K on Jan 9, 2026 about FDA-identified NDA deficiencies preceded a -37.04% move, while the Jan 30, 2026 Complete Response Letter announcement on Feb 2 coincided with a 38.98% gain as investors reacted to packaging-focused issues and a planned Q3 2026 resubmission. Subsequent updates, including a new CMO appointment and clinical data presentation plans, produced relatively modest single‑digit price moves. Today’s conference participation fits within these lower-impact event types.
Market Pulse Summary
This announcement highlights AQST’s participation in an investor-focused healthcare conference, providing another venue to discuss its pipeline and regulatory plans with the market. In recent months, the most consequential developments have centered on FDA feedback and a Complete Response Letter for Anaphylm, which drove substantial volatility. Investors following this update may focus on how management frames regulatory timelines, clinical data, and commercialization strategy during the presentation and subsequent one‑on‑one meetings.
AI-generated analysis. Not financial advice.
WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, which is a virtual event.
The Aquestive team will be presenting on February 26th, at 12 pm ET; management will also be hosting one-on-ones with investors that same day.
A webcast of the presentation will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine prodrug) topical gel for various potential dermatological conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm™ (dibutepinephrine) sublingual film, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com
FAQ
When will Aquestive (AQST) present at the Oppenheimer 2026 conference?
How can investors watch the Aquestive (AQST) presentation from Oppenheimer 36th Annual Healthcare Life Sciences Conference?
Will there be a replay of Aquestive's (AQST) conference presentation and for how long?
What investor access will Aquestive (AQST) management provide at the Oppenheimer conference?
Where can I find details and timing for Aquestive's (AQST) conference appearance?
Is the Oppenheimer 36th Annual Healthcare Life Sciences Conference appearance by Aquestive (AQST) virtual or in-person?
